@article{3030866,
    title = "Liver resection and ablation for squamous cell carcinoma liver
metastases",
    author = "Engstrand, J. and de Carvalho, L. F. Abreu and Aghayan, D. and and Balakrishnan, A. and Belli, A. and Bjornsson, B. and Dasari, B. V. M. and and Detry, O. and Di Martino, M. and Edwin, B. and Erdmann, J. and and Fristedt, R. and Fusai, G. and Gimenez-Maurel, T. and Hemmingsson, O. and and Salinas, C. Hidalgo and Isaksson, B. and Ivanecz, A. and Izzo, F. and and Knoefel, W. T. and Kron, P. and Lehwald-Tywuschik, N. and Lesurtel, and M. and Lodge, J. P. A. and Machairas, N. and Marino, M. V. and Martin, and V. and Paterson, A. and Rystedt, J. and Sandstrom, P. and Serrablo, A. and and Siriwardena, A. K. and Taflin, H. and Van Gulik, T. M. and Yaqub, S. and and Ozden, I. and Ramia, J. M. and Sturesson, C. and E AHPBA Sci Res and Comm",
    journal = "BJS OPEN",
    year = "2021",
    volume = "5",
    number = "4",
    publisher = "Oxford University Press",
    doi = "10.1093/bjsopen/zrab060",
    abstract = "Background: Limited evidence exists to guide the management of patients
with liver metastases from squamous cell carcinoma (SCC). The aim of
this retrospective multicentre cohort study was to describe patterns of
disease recurrence after liver resection/ablation for SCC liver
metastases and factors associated with recurrence-free survival (RFS)
and overall survival (OS).
Method: Members of the European-African Hepato-Pancreato-Biliary
Association were invited to include all consecutive patients undergoing
liver resection/ablation for SCC liver metastases between 2002 and 2019.
Patient, tumour and perioperative characteristics were analysed with
regard to RFS and OS.
Results: Among the 102 patients included from 24 European centres, 56
patients had anal cancer, and 46 patients had SCC from other origin. RFS
in patients with anal cancer and non-anal cancer was 16 and 9 months,
respectively (P = 0.134). A positive resection margin significantly
influenced RFS for both anal cancer and non-anal cancer liver metastases
(hazard ratio 6.82, 95 per cent c.i. 2.40 to 19.35, for the entire
cohort). Median survival duration and 5-year OS rate among patients with
anal cancer and non-anal cancer were 50 months and 45 per cent and 21
months and 25 per cent, respectively. For the entire cohort, only
non-radical resection was associated with worse overall survival (hazard
ratio 3.21, 95 per cent c.i. 1.24 to 8.30).
Conclusion: Liver resection/ablation of liver metastases from SCC can
result in long-term survival. Survival was superior in treated patients
with liver metastases from anal versus non-anal cancer. A negative
resection margin is paramount for acceptable outcome."
}